High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer.

IF 5.6 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Cancer Biology & Medicine Pub Date : 2025-07-04 DOI:10.20892/j.issn.2095-3941.2025.0038

Yuling Xiao, Hang Zhang, Yi Xiao, Ying Wang, Jing Zhang, Qi Hua, Pengchen Hu, Xinyan Lyu, Weihua Shou, Xin Hu, Zhiming Shao, Yizhou Jiang, Wei Huang, Jinxiu Shi

{"title":"High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer.","authors":"Yuling Xiao, Hang Zhang, Yi Xiao, Ying Wang, Jing Zhang, Qi Hua, Pengchen Hu, Xinyan Lyu, Weihua Shou, Xin Hu, Zhiming Shao, Yizhou Jiang, Wei Huang, Jinxiu Shi","doi":"10.20892/j.issn.2095-3941.2025.0038","DOIUrl":null,"url":null,"abstract":"Objective: While immunotherapy holds great potential for triple-negative breast cancer (TNBC), the lack of non-invasive biomarkers to identify beneficiaries limits the application.Methods: Paired baseline, on-treatment, and post-treatment plasma samples were collected from 195 TNBC patients receiving anti-PD-1 immunotherapy in this retrospective study conducted at the Fudan University Shanghai Cancer Center (FUSCC) for sequential high-precision proteomic profiling.Results: ARG1, NOS3, and CD28 were identified as plasma proteins significantly associated with the response to immunotherapy in neoadjuvant settings or in advanced stages of TNBC. Matched single-cell RNA sequencing data were incorporated to correlate peripheral plasma with the tumor microenvironment. Furthermore, the Plasma Immuno Prediction Score was developed to demonstrate significant predictive power for evaluating the efficacy and prognosis of patients undergoing neoadjuvant immunotherapy.Conclusions: The results underscore the importance of systemic immunity in the immunotherapy response and support the use of plasma protein profiles as a feasible tool for enhancing personalized management of immunotherapy in breast cancer.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biology & Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20892/j.issn.2095-3941.2025.0038","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: While immunotherapy holds great potential for triple-negative breast cancer (TNBC), the lack of non-invasive biomarkers to identify beneficiaries limits the application.

Methods: Paired baseline, on-treatment, and post-treatment plasma samples were collected from 195 TNBC patients receiving anti-PD-1 immunotherapy in this retrospective study conducted at the Fudan University Shanghai Cancer Center (FUSCC) for sequential high-precision proteomic profiling.

Results: ARG1, NOS3, and CD28 were identified as plasma proteins significantly associated with the response to immunotherapy in neoadjuvant settings or in advanced stages of TNBC. Matched single-cell RNA sequencing data were incorporated to correlate peripheral plasma with the tumor microenvironment. Furthermore, the Plasma Immuno Prediction Score was developed to demonstrate significant predictive power for evaluating the efficacy and prognosis of patients undergoing neoadjuvant immunotherapy.

Conclusions: The results underscore the importance of systemic immunity in the immunotherapy response and support the use of plasma protein profiles as a feasible tool for enhancing personalized management of immunotherapy in breast cancer.

查看原文本刊更多论文

高精度免疫相关血浆蛋白质组学分析预测三阴性乳腺癌患者对免疫治疗的反应

目的：虽然免疫疗法对三阴性乳腺癌（TNBC）具有巨大的潜力，但缺乏非侵入性生物标志物来识别受益人限制了其应用。方法：在复旦大学上海癌症中心（FUSCC）进行的这项回顾性研究中，收集了195名接受抗pd -1免疫治疗的TNBC患者的基线、治疗中和治疗后血浆样本，进行了序列高精度蛋白质组学分析。结果：ARG1、NOS3和CD28被鉴定为血浆蛋白，与新辅助治疗或晚期TNBC的免疫治疗反应显著相关。结合匹配的单细胞RNA测序数据，将外周血浆与肿瘤微环境相关联。此外，血浆免疫预测评分在评估接受新辅助免疫治疗的患者的疗效和预后方面显示出显著的预测能力。结论：这些结果强调了全身免疫在免疫治疗反应中的重要性，并支持血浆蛋白谱作为一种可行的工具，用于加强乳腺癌免疫治疗的个性化管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Biology & Medicine Medicine-Oncology

CiteScore

9.80

自引率

3.60%

发文量

1143

审稿时长

12 weeks

期刊介绍： Cancer Biology & Medicine (ISSN 2095-3941) is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China.